The high-speed train planning a Houston-Dallas route now has a builder on board the project

Right on track

The high-speed train now has a new builder onboarded for the project. Photo of the N700 courtesy of © JR Central

The Texas high-speed train that plans to zip between Houston and Dallas still has some obstacles to plow through, but the project now has a builder at least.

Texas Central, the developer of the Texas Bullet Train, has signed a contract with Salini Impregilo, an Italian construction company and one of the largest civil engineering contractors in the world, and its American subsidiary, Lane Construction.

"This agreement brings us one step closer to beginning construction of the civil infrastructure segments of the project," said Texas Central CEO Carlos F. Aguilar, in a release.

The train still can't move forward because it doesn't own all of the land necessary for the route.

But if/when it does get the land, Salini Impregilo will do the following:

  • supply the civil and infrastructure scope, including the design and construction of the viaduct and embankment sections along the entire route
  • install the track system
  • oversee alignment and construction of all buildings and services that will house maintenance and other rail system equipment

Salini-Lane had previously provided front-end engineering and design for the train's civil infrastructure, as well as an analysis of construction costs and schedule estimates.

"Salini-Lane's unmatched track record with rail infrastructure and, very specifically, its world-class high-speed rail expertise across the globe will be central to the completion of America's first end-to-end high-speed rail system," Aguilar says.

Salini's CEO Pietro Salini says in a statement that the company is both thrilled and honored to bring its large-scale railway expertise to the project.

Salini Impregilo is active in more than 50 countries on five continents, with experience building more than 4,000 miles of railway infrastructure around the world. It has built high-speed train projects in Europe and some iconic projects in the world, including the expansion of the Panama Canal.

Although the company has worked in the U.S. since the 1980s, it expanded its presence in 2016 when it merged with The Lane Construction Corporation, a U.S.-based company with almost 130 years of experience in infrastructure work.

The Texas train will be based on Central Japan Railway's Tokaido Shinkansen train system, which is considered the safest mass transportation system in the world.

The system has transported more than 10 billion passengers in 54-plus years, with no fatalities or injuries from operations, and has an impeccable on-time performance record.

It will debut a new train, the Shinkansen N700S, the sixth generation of this train, before the 2020 Olympics.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

UH research team receives grant to fight aggressive pediatric cancer

cancer research

Researchers at the University of Houston have received a $3.2 million grant from the National Institutes of Health to help find innovative ways to treat Rhabdomyosarcoma, or RMS.

According to a statement from the university, RMS is a malignant soft tissue sarcoma that has a higher incidence in young children and is responsible for 8 percent of pediatric cancer cases with a relatively low survival rate.

One way UH is working on the issue is by studying how and why RMS cells, which are found most often in muscle tissue, divide uncontrollably without ever maturing into normal muscle cells. The researchers aim to tackle a target inside RMS cells known as TAK1, which plays a key role in regulating cell growth.

“By targeting TAK1, we aim to stop the cancer at its source and help the cells develop normally,” Ashok Kumar, the Else and Philip Hargrove Endowed Professor of Drug Discovery at the UH College of Pharmacy and director of the Institute of Muscle Biology and Cachexia, said in a news release. “This approach could lead to new and better treatments for RMS.”

According to UH, preliminary results demonstrated that TAK1 is highly activated in embryonal RMS cells, which are found in younger children; alveolar RMS cells, which are found in older children and teens; and human RMS samples. This suggests that the protein plays a major role in the development of this form of cancer.

The team still aims to uncover how the protein helps RMS cancer grow and plans to evaluate how blocking TAK1 can be used as a therapeutic.

“Blocking TAK1, either by changing the genes (genetic approaches) or using drugs (pharmacological approaches), can stop certain harmful behaviors in cancer cells,” Kumar added. “This was tested both in lab-grown cells and in living models, showing that TAK1 is a key target to control RMS cancer’s spread and aggressiveness, and inhibits tumor formation.”

Texas A&M expands innovative Dog Aging Project via $7 million grant

pet project

The Texas A&M College of Veterinary Medicine and Biomedical Sciences has received a $7 million grant from the National Institutes of Health to support its Dog Aging Project.

The DAP is a research project that was launched in 2019 by Texas A&M and the University of Washington School of Medicine and has enrolled over 50,000 dogs to date, according to a release. The program studies various breeds of companion dogs and studies the effects of aging to help develop a better understanding of what can lead to an expanded, healthy canine life, which can also assist with human aging knowledge.

The NIH funds will be used to expand a clinical trial studying how the drug rapamycin, also called sirolimus, can extend the lives of companion dogs.

The project, known as Test of Rapamycin In Aging Dogs (TRIAD), is the third DAP clinical trial involving the drug rapamycin. The drug has previously been used as an immunosuppressant during organ transplants in humans. Past DAP studies reported that the drug appears to improve cardiac function in dogs.

“Rapamycin works by modifying the cells’ energy balance and energy handling,” Dr. Kate Creevy, DAP chief veterinary officer and a professor in the VMBS’ Department of Small Animal Clinical Sciences, said in a news release. "It seems to mimic the effects that happen in people or animals who do intermittent fasting. There is a lot of interest in intermittent fasting as a technique that can improve health, particularly healthy aging, and some of the pharmaceutical effects of rapamycin make the same changes at the cellular level.”

So far, 170 dogs are in the trial at 20 sites, with the goal of expanding to 580 dogs enrolled in multiple cities across the country. Dogs must be over 7 years old and in good general health to participate. They should also weigh at least 44 pounds. Owners are required to bring their dogs to one of TRIAD’s participating clinical sites every six months for three years. The Texas clinical sites are in College Station and North Texas.

“Dogs experience many of the age-related cognitive, sensory, neuropathologic and mobility changes that are common in older humans,” Dr. May Reed, a geriatrician at the University of Washington School of Medicine and another primary investigator in the study, said in the release. “The possibility that rapamycin might delay any of the alterations that contribute to cognitive impairment and functional decline is very exciting and has huge translational potential.”

“We get to learn how to support both dog and human aging at the same time. Our research is also powered by owners’ commitments to the health of their dogs, and that’s what makes our work both possible and meaningful,” Creevy added. “We’re very grateful to them.”

Houston unicorn startup named North American Company of the Year

top honor

Houston-based geothermal energy startup Fervo Energy has been named North American Company of the Year by research and consulting firm Cleantech Group.

Fervo appears on this year’s Global Cleantech 100, Cleantech Group’s annual list of the world’s most innovative and promising cleantech companies

Houston companies Syzygy Plasmonics and Vaulted Deep also made the Global Cleantech 100 list this year.

“These innovators give us reasons to be optimistic about the future. Their groundbreaking work demonstrates that progress toward net-zero remains possible and inspires us to double down on the challenge of addressing climate change,” says Richard Youngman, CEO of Cleantech Group.

Fervo was honored during a Jan. 27 awards dinner at Cleantech Forum North America, an event hosted by Cleantech Group. Co-founder and CEO Tim Latimer accepted the North American Company of the Year award on behalf of Fervo.

“We have always been honored to be part of the Global Cleantech 100,” Latimer says in a LinkedIn post. “Being recognized for the fourth consecutive year and named the ‘North American Company of the Year’ is a testament to our relentless pursuit of innovation in the energy sector. The demand for clean, firm power has never been more urgent, and we are proud to lead the way.”

Founded in 2017, Fervo is now a unicorn, meaning its valuation as a private company has surpassed $1 billion. The startup’s valuation is estimated at $1.4 billion. According to PitchBook data, the company raised $634 million in VC funding in Q4. Read more here.

--

This article originally appeared on our sister site, Energy Capital.

View All Listings